A prospective observational study to establish an optimal Adalimumab serum trough level (ATL) range in rheumatoid arthritis patients with good clinical response

Trial Profile

A prospective observational study to establish an optimal Adalimumab serum trough level (ATL) range in rheumatoid arthritis patients with good clinical response

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top